The Federal Circuit in its precedential decision in Phigenix v ImmunoGen has ruled the petitioner lacked standing to appeal a Patent Trial and Appeal Board final written decision because of insufficient evidence to show an “injury-in-fact”
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
As trade secret filings rise due to AI development and economic espionage concerns, firms are relying on proactive counselling to help clients navigate disputes
IP firm leaders share why they remain positive in the face of falling patent applications from US filers, and how they are meeting a rising demand from China